可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]施仲伟.心血管病危险控制的内容与方法[J].中华心血管病杂志,2001,29(7):441-442.
[2] Kannel W B.Potency of vascular risk factors as the basis for antihypertensive therapy[J].Eur Heart J,1992,13(SupplG):34-42.
[3]Behar S.Lowering fibrinogen levels:clinical update.BIP Study Group.Bezafibrate Infarction Prevention [J].Blood Coagul Fibrinolysis,1999,10(Suppl1):S41-S43.
[4]莫亚岚.稳定性、不稳定性心绞痛患者血浆纤维蛋白原、血糖、胆固醇的观察[J].数理医药学杂志,2001,14(4):308.
[5]马建林,毛焕元.老年血栓形成前状态及其防治的研究进展[J].心脏杂志,2002,14(2):170-172.
[6]Sarsh H,Olivier BB,Andrew G.Molecules in focus fibrinogen[J].Int J Biochem Cell Biol,1999,31:741-746.
[7]Gil M,Zarebinski M,Olszewski R.Fibrinogen serum levels in
patients with stable coronary artery disease and acute coronary syndrome[J].Pol Merkuriusz Lek,2000,50:531-532.
[8] Dominiczak MH.Risk factors for coronary disease:the time for a paradigm shift?[J].Clin Chem Lab Med,2001,39:907-919.
[9] Kannel W B.Influence of fibrinogen on cardiovascular disease[J].Drugs,1997,54(Suppl3):32-40.
[10] Kannel WB. Hazards, risks ,and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure [J].Cardiovasc Drugs Ther,1997,11(Suppl1):199-212.
[11]Goracy I, Goracy J, BrykczynskiM. Fibrinogen (Fb)concentrations in patients with ischaemic heart disease undergoing coronary angiography [J].Pol Arch Med Wewn,2001,106:551-556.
[12]Thompson WD,SmithEB. Atherosclerosis and the coagulation system[J].JPathol,1989,159:97-106.